ARTBIO is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) to transform cancer treatment. ARTBIO's approach centers on utilizing the alpha-emitting isotope Pb212 to target cancer cells while minimizing damage to healthy tissues.

Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Number of employees in Switzerland
    10-19
Key business

You may also be interested in